Hospira Joins Biosimilars Race With FDA Application

Law360, New York (January 12, 2015, 6:26 PM ET) -- Hospira Inc. announced on Monday that it is asking the U.S. Food and Drug Administration to approve a copycat version of Amgen Inc.’s Epogen and Johnson & Johnson's Procrit, marking the fourth proposed biosimilar along an Affordable Care Act pathway.



Hospira’s product is an anti-anemia biosimilar called Retacrit that European regulators cleared in 2007. Its active ingredient, epoetin zeta, is viewed as comparable to epoetin alfa, the active ingredient in Epogen and Procrit.



The Retacrit application was submitted to the FDA on Dec. 16. A spokeswoman...

To view the full article, register now.